Lab21 signs a license with Celera for one of the first diagnostic tests for cirrhosis risk in hepatitis C patients

Lab21 signs a license with Celera for one of the first diagnostic tests for cirrhosis risk in hepatitis C patients

Lab21 announced that it has obtained a licence from Celera, an Applera Corporation business, to provide access to its test for cirrhosis risk in patients with chronic hepatitis C viral (HCV) infection in the UK and Ireland. The test, known as CRS7, is the first clinical test capable of pre ... more

Celera Genomics Receives NIH Grant to Develop and Commercialize Avian Flu Diagnostic Test

Celera Genomics, an Applera Corporation business, announced that the National Institutes of Health (NIH) has awarded Celera approximately $900,000 to develop and commercialize an in vitro diagnostic (IVD) test for the highly pathogenic influenza A/H5 virus (Asian lineage, H5N1). The test Ce ... more

Celera and Collaborators Discover Genetic Markers Associated with Early-onset Heart Attacks

Celera Genomics, an Applera Corporation business, the University of California, San Francisco (UCSF), Cleveland Clinic, Case Western Reserve University and Brigham Young University, announced a publication describing two novel genetic markers associated with an increased risk for myocardial ... more

Applied Biosystems, 454 Life Sciences and Illumina Join 1000 Genomes Project

Leaders of the 1000 Genomes Project announced that three firms that have pioneered development of new sequencing technologies have joined the international effort to build the most detailed map to date of human genetic variation as a tool for medical research. The new participants are: Appl ... more

BIOTECON Diagnostics signs license agreement with Applera Corporation

Applera and BIOTECON Diagnostics (BCD) announced a non-exclusive, worldwide license agreement relating to PCR technology for Food Testing Applications and Genetically-Modified Organism (GMO) Testing Applications: BIOTECON Diagnostics has acquired important rights with the PCR licence. In ... more

Lab21 signs a license with Celera for one of the first diagnostic tests for cirrhosis risk in hepatitis C patients

Lab21 announced that it has obtained a licence from Celera, an Applera Corporation business, to provide access to its test for cirrhosis risk in patients with chronic hepatitis C viral (HCV) infection in the UK and Ireland. The test, known as CRS7, is the first clinical test capable of pre ... more

Lab21 Wins Biomedical Project of the Year Award

Lab21 Limited has won the BioNow Biomedical Project of the Year Award for its MycAssay product line.  The BioNow Biomedical Project of the Year Award recognises individuals or organisations who have demonstrated an innovative solution to a specific industry problem. Lab21’s MycAssay Aspergi ... more

Lab21 Announces Positive Results for Aspergillus Detection in Critical Care and Haematology Patients

Lab21 Limited has announced the completion of an evaluation of a commercial PCR test, its MycAssayTM Aspergillus assay, to detect invasive Aspergillosis (IA) in a mixed population of 158 patients with underlying haematological or critical illness. The prospective evaluation was performed by ... more

Lab21 Extends CPA Accreditation

Lab21 Limited has announced that its Clinical Laboratory Division has extended its Clinical Pathology Accreditation (CPA) scope to include Molecular Biology and Virology in addition to Biochemistry. The accreditation was awarded by Clinical Pathology Accreditation (UK), the quality assuranc ... more